logo-loader
Faron Pharmaceuticals Ltd

Faron Pharma “extremely happy” with progress of Clevegen trial

The biopharma firm said its Clevegen treatment could potentially induce a "stronger immune response" at lower doses, increasing its safety margins

Faron Pharmaceuticals Ltd - Faron Pharma “extremely happy” with progress of Clevegen trial

Faron Pharmaceuticals Oy's (LON:FARN) Clevegen cancer treatment has shown its safety credentials in its initial clinical trials.

The biopharma firm said that feedback from a dose escalation study had confirmed that Clevegen had “good tolerability” across all dosing levels tested with no dose limiting toxicity observed, adding that lower doses could potentially induce a “stronger immune response” and was now considering tests on lower dose levels of around 0.1-1 milligrams per kilo (mg/kg) rather than higher dosages of 20 mg/kg as previously planned.

WATCH: 'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron also said in line with advice from the study’s data monitoring committee it would expand its patient cohort for part I of the trial to 30 to determine optimal dosage before moving to part II.

“Good safety was the first priority of Part I and now we have obtained that status”, said Faron’s chief executive Markku Jalkanen.

He added that if the optimal dose for Clevegen was at the lower end of the scale it would provide an “unusually high safety margin” for the treatment either alone or in combination with other cancer therapies.

Quick facts: Faron Pharmaceuticals Ltd

Price: 130 GBX

Market: AIM
Market Cap: £51.16 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 days, 15 hours ago

RNS

Second Price Monitoring Extn

1 week, 2 days ago

Price Monitoring Extension

1 week, 2 days ago

Matins Trial Update

1 week, 4 days ago

Notice of EGM

2 weeks, 2 days ago

Holdings in Company

3 weeks, 4 days ago

Interim results

3 weeks, 6 days ago

2 min read